

1 **Short title: Snotwatch COVID-toes: An ecological study**

2 **Long title: Snotwatch COVID-Toes: An ecological study of**
3 **chilblains and COVID-19 diagnoses in Victoria, Australia**

4 **Authors:**

5 **Rana Sawires, BMedSci (Hons)^{1,2*}, Christopher Pearce, PhD⁷, Michael Fahey, PhD^{3,4}, Hazel**

6 **Clothier^{2,6} PhD, Karina Gardner, MClEpi⁷, Jim Buttery, M.D.^{1,2,6}**

7 ¹Department of Paediatrics, Faculty of Medicine, Nursing and Health Sciences, Monash
8 University, Victoria, Australia.

9 ²Murdoch Children's Research Institute, Royal Children's Hospital, Parkville, Victoria,
10 Australia.

11 ³Department of Neurology, Monash Children's Hospital, Victoria, Australia.

12 ⁴Neurogenetics Department, Monash Paediatrics, Monash University, Victoria, Australia.

13 ⁵School of Population & Global health, University of Melbourne, Victoria, Australia.

14 ⁶Child Health Informatics, Department of Paediatrics, University of Melbourne, Victoria,
15 Australia.

16 ⁷Outcome Health

17 *** Corresponding Author: Rana Sawires**

18 Email: rana.sawires@monash.edu

19 Abstract

20 Background

21 The COVID-19 pandemic has caused widespread illness with varying clinical manifestations.

22 One less-commonly-reported presentation of COVID-19 infection is chilblain-like lesions.

23 Aims

24 We conducted an ecological analysis of chilblain presentations in comparison with
25 confirmed and suspected COVID-19 infections in a primary care setting to establish that a
26 relationship exists between the two.

27 Study Design

28 Our study collated data from three Primary Health Networks across Victoria, Australia, from
29 2017-2021, to understand patterns of chilblain presentations prior to and throughout the
30 pandemic. Using a zero-inflated negative binomial regression analysis, we estimated the
31 relationship between local minimum temperature, COVID-19 infections and the frequency
32 of chilblain presentations.

33 Results

34 We found a 5.72 risk ratio of chilblain incidence in relation to COVID-19 infections and a
35 3.23 risk ratio associated with suspected COVID-19 infections. COVID-19 infections were
36 also more strongly associated with chilblain presentations in 0-16-year-olds throughout the
37 pandemic in Victoria.

38 Conclusion

39 Our study statistically demonstrates that chilblains are significantly associated with COVID-
40 19 infections in a primary care setting. This has major implications for clinicians aiming to
41 diagnose COVID-19 infections or determine the cause of a presentation of chilblains.

42 Additionally, we demonstrate the utility of large-scale primary care data and its potential
43 application to monitoring the spread of COVID-19 infections across the state, supporting
44 current epidemiological efforts for COVID-19 tracking.

45 Introduction

46 The global coronavirus disease-19 (COVID-19) pandemic caused widespread illness and
47 global economic disruption. In addition to the more common respiratory symptoms,
48 cutaneous manifestations were reported in some patients with COVID-19^{1,2} particularly
49 chilblain-like skin changes.³⁻⁵ Chilblains are an inflammatory dermatological condition
50 affecting the acral regions of the body, often affecting women and middle-aged adults.⁶
51 They present more frequently in wet-weather seasons, such as late winter and early spring⁶
52 and are caused by abnormal vasospasm in response to cold associated with an inflammatory
53 infiltrate composed of T cells, B cells and macrophages.⁶ Until COVID-19, infectious causes
54 were not thought to be an association.⁷

55 Finding a strong link between COVID-19 and chilblains has proven elusive. While an
56 international register of people with skin eruptions revealed 45% of 505 patients had
57 respiratory symptoms consistent with COVID-19,⁸ other studies found no serological
58 evidence of COVID-19 infection in people with chilblains.⁹ Given the difficulty synthesising
59 these contradictory findings, we aimed to establish and quantify the temporal relationship
60 of chilblains with COVID-19 in Victoria, Australia in an ecological framework. Using such a
61 large dataset lays the groundwork for future research and has substantial public health and
62 epidemiological implications for tracking COVID-19 viral spread in the community.

63 Methods

64 Data Collection

65 Data were extracted using the POLAR (POpulation Level Analysis and Reporting) analytics
66 program developed by Outcome Health. The POLAR system collects and processes data

67 from constituent practices across Primary Health Networks (PHNs). PHNs contributing to
68 this study are located in Eastern Victoria (Eastern Melbourne, Gippsland and South-Eastern
69 Melbourne) representing 537 general practices with a pooled catchment of 3.65 million
70 patients (Figure 1). POLAR is an end-to-end analytics platform that collects and processes
71 electronic medical record information from general practices on behalf of PHNs. POLAR is
72 both a patient-level clinical decision support tool and a population health analytics platform.
73 Practices contributing data via the POLAR platform can engage in research activity by
74 agreeing to share de-identified snapshots of their data for ethics-reviewed, PHN-approved
75 research. Data collected by the POLAR system and shared for research is processed,
76 mapped, coded (to SNOMED codes), curated and redacted according to POLAR's Data De-
77 identification Decision-Making Framework (developed with guidance from the Office of the
78 Australian Information Commissioner). This yields a longitudinal dataset stripped of
79 identifiable information.

80

81 *Figure 1: Data was obtained from three Primary Health Networks, servicing 3.65 million*
82 *people in Victoria, Australia 2017-2021 (blue). Image adapted from Australian Government*
83 *Department of Health.*¹⁰

84

85 [Study design and cohort](#)

86 Using data collected from participating General Practices (GPs) on behalf of PHNs, we
87 conducted a retrospective ecologic cohort analysis from January 2017- September 2021.
88 Inclusion criteria were any diagnoses of chilblains, COVID-19 disorder, or suspected COVID-
89 19 disorder recorded in any Victorian general practice located in one of the three

90 participating PHNs. SNOMED codes¹¹ are an organised set of medical terms which provide
91 codes, synonyms and definitions for terms used in clinical documentation and reporting and
92 are used for organising data collected by POLAR. Our study cohort was generated using
93 SNOMED codes for conditions of interest: chilblains (SNOMED code 37869000), COVID-19
94 disorder (SNOMED code 840539006), and suspected COVID-19 (SNOMED code 840544004).
95 Data extracted included: the patient's age in years and the date of diagnosis. Data were de-
96 identified. COVID-19 disorder is a code used for patients who have had a positive
97 polymerase chain reaction (PCR) test for COVID-19 infection and recorded in the GP
98 software. Suspected COVID-19 codes are used for symptomatic patients who have not had a
99 positive PCR test for COVID-19 infection.

100 Additionally, we obtained local daily minimum temperature data from all weather stations
101 in Victoria from the Bureau of Meteorology (BOM) from January 2017- September 2021 and
102 aggregated these data across the state. This yielded average statewide minimum
103 temperature data.

104 All data were then aggregated by the week of the year, where the weeks were calculated
105 from Monday to Sunday. The first and last weeks of the year were included independently
106 regardless of the day of the week they started or ended, respectively.

107 [Statistical Analysis](#)

108 The coding program, R (version 4.0.2),¹² was applied through RStudio (version 1.2.5)¹³ for
109 statistical analysis of temporal data. Following fit testing of the distribution of our data, we
110 determined that conducting a zero-inflated negative binomial regression analysis would be
111 the most suitable technique for modelling our data. We created a multivariate model, which
112 used weekly minimum temperature, COVID-19 and suspected COVID-19 diagnoses to

113 predict chilblains. To meaningfully determine the effect of temperature on chilblains, we
114 used a negative transformation of the temperature data.
115 Additionally, to assess the possible lag in any association between chilblains and the COVID-
116 19 diagnoses, we created lead and lag models for our datasets, eight exploring leads in
117 chilblains diagnoses, and eight exploring lags. We assessed the relationship between COVID-
118 19 and chilblains in different age groups (0-16 years, 17-49 years, and 50 years and over). To
119 assess the effect of COVID-19 diagnoses on chilblains presentations we compared the risk of
120 chilblains when COVID-19 diagnoses were present at or above the 95th percentile of their
121 maximum rate to the 50th centile of their maximum rate. Our significance level was set at
122 $p < 0.01$.

123 [Ethics approval](#)

124 Ethical approval for Snotwatch projects was obtained through our primary Human Research
125 Ethics Committee (HREC) in Monash Health from 24th July 2019 (NMA/ERM Reference
126 Number: 53611).

127 For the use of data from POLAR GP, additional approval was obtained under Monash Health
128 (Monash Health Reference Number: RES-18-0000-232A, NMA HREC Reference Number:
129 HREC/18/MonH/345).

130 The extraction, storage and management of data on the POLAR platform has ethics approval
131 from the RACGP National Research and Evaluation Research Committee (Protocol ID: 17-
132 008). Ethics approval for this project was granted by the Monash Health Human Research
133 Ethics Committee (Ref No: 21-013L).

134 Results

135 Cohort Demographics

136 From January 2017-September 2021, there were a total of 6,846 chilblains diagnoses across
137 the three participating PHNs in Victoria. The distribution of chilblains across the age groups
138 approximately matched that of the Victorian population.

139 A total of 3,687 diagnoses of COVID-19 disorders and 4,688 diagnoses of suspected COVID-
140 19 were recorded in a GP setting from January 2020- September 2021. We excluded four
141 diagnoses of COVID-19 disorder and one diagnosis of suspected COVID-19 disorder that
142 occurred before January 2020 as these were assumed to be errors in the system. These
143 exclusions are unlikely to alter the findings of our study.

144 Bureau of Meteorology Temperature Data

145 Victoria is a region with a moderate climate in the Southern Hemisphere. We obtained
146 aggregated BOM for minimum temperature across the state of Victoria. The median
147 minimum temperature for Victoria was 8.12 degrees Celsius (Interquartile Range 5.53-
148 12.08). The minimum and maximum temperatures for each year remained consistent, with
149 only a slightly lower maximum temperature in 2021, which is likely because the data ended
150 in September, prior to the beginning of the 2021 summer season.

151 Data Visualisation

152 A clear peak of chilblains presentations was evident in winter of each year. This coincided
153 with decreasing temperature throughout the 5-year period. COVID-19 disorder, and
154 suspected COVID-19 disorder mirrored the peak in chilblains in 2020 very closely but lagged
155 the chilblains peak in 2021. (Figure 2)

156

157 *Figure 2: Weekly number of chilblains diagnoses, COVID-19 diagnoses and Minimum*

158 *Temperature in Victoria 2017-2021*

159

160 *Associations of chilblains with COVID-19 diagnoses and average minimum*

161 *temperature*

162 In Victoria, chilblains were significantly associated with a reduction in temperature, having a

163 risk ratio (RR) of 1.33 (99%CI 1.27-1.40) per 1°Celsius. When comparing the 95th centile to

164 50th centile of COVID-19 and suspected COVID-19 diagnoses, there was a 5.72 RR (99%CI

165 2.27-14.44) and 3.23 RR (99%CI 1.32-7.91) of chilblains presentations respectively. Lead and

166 lag analyses did not demonstrate any meaningful temporal associations between chilblains

167 and COVID-19 in a general practice setting. The complete table is shown in S1 Appendix A.

168 Both COVID-19 diagnosis and suspected COVID-19 also had a greater association with

169 chilblains in 0-16-year-old children with chilblains (5.96 RR and 4.34 RR respectively). The

170 size of the association reduced with each age group, with only a 3.03 RR and 1.69 RR

171 respectively with chilblains in people 50 years and over. The results from our subgroup

172 analyses are shown in Table 1.

173

174 *Table 1: Associations between COVID-19 disorder, suspected COVID-19 disorder and*

175 *decreasing temperature with chilblains in different age groups. All results were statistically*

176 *significant.*

	RR OF CHILBLAINS ALL COHORT (99% CI)	RR OF CHILBLAINS IN 0–16-YEAR- OLDS (99% CI)	RR OF CHILBLAINS IN 17–49- YEAR-OLDS (99% CI)	RR OF CHILBLAINS IN 50 YEARS AND OVER (99% CI)
COVID-19 DISORDER	5.72 (2.27-14.44)	5.96 (1.68-21.18)	4.98 (2.00-12.38)	3.03 (1.42-6.46)
SUSPECTED COVID-19	3.23 (1.32-7.91)	4.34 (1.31-14.32)	3.59 (1.49-8.68)	1.69 (0.84-3.40)
DECREASING TEMPERATURE (PER 1°C)	1.33 (1.27-1.40)	1.27 (1.15-1.41)	1.32 (1.24-1.40)	1.29 (1.23-1.36)

177

178 Discussion

179 To our knowledge, this is the largest population-level ecological study of the relationship
180 between COVID-19 and presentations of chilblains in a GP setting. We found increases in
181 diagnoses of chilblains in participating PHNs that could be significantly correlated with
182 COVID-19 circulation in Victoria. Our study confirms findings in most of the existing
183 literature. Since the beginning of 2020, chilblains have been reported in conjunction with
184 COVID-19 disorder in several European case series and one epidemiological study in
185 California.^{3, 4, 14} Nevertheless, it is still uncertain whether COVID-19 infection is the cause of
186 these presentations. While in some cases, a causal relationship has been supported by
187 positive PCR results^{4, 15} or serology,¹⁶ the vast majority of studies show a low rate of PCR
188 positivity for COVID-19 diagnoses in patients who present with chilblains.^{17, 18}

189 The mechanism of chilblains presentations in COVID-19 infectious is unknown. One
190 systematic review showed that the cutaneous manifestations of COVID-19 infection could
191 be due to increased ACE2 expressions in the skin, although the specific method of erythema
192 development in COVID-19 infection remains unclear.¹⁹

193 Additionally, there is uncertainty surrounding the diagnosis of cutaneous manifestations of
194 COVID-19 infections. Histological confirmation of chilblains diagnosis requires a skin biopsy
195 that demonstrates a superficial and deep lymphocytic inflammatory infiltrate in a lichenoid,
196 perivascular, and peri-eccrine distribution.²⁰ However, there is no consensus on whether
197 chilblains in the context of COVID-19 infections have the same histological features as
198 idiopathic chilblains.¹⁶

199 In light of the difficulty in delineating the pathophysiological association between COVID-19
200 infection and chilblains, it has been suggested that behaviour changes during lockdowns,
201 such as not wearing shoes or socks in the home, leaving extremities more exposed to the
202 cold, could explain the possible increase in the number of chilblains presentations over the
203 course of the pandemic.²¹ One explanation is that in response to COVID-19 infection, a high
204 level of type I interferons (IFN) (as seen in familial chilblains lupus) could itself be the cause
205 for the development of chilblains.²² Further research is required to ascertain whether this is
206 the case.

207 Our findings showed that COVID-19 disorder diagnoses were most strongly associated with
208 chilblains presentations in the same week, whereas suspected COVID-19 disorder was
209 associated with chilblains presentations in the preceding and following weeks more
210 strongly.

211 Studies have suggested that various cutaneous manifestations of COVID-19 can precede, lag
212 or coincide with extracutaneous symptoms of COVID-19 infection or a confirmed COVID-19
213 diagnosis.² More specifically, chilblain-like lesions are the latest to present, with a 2-8-week
214 lag following respiratory COVID-19 symptoms.^{5, 16}

215 Chilblains may also be a late manifestation of the disease and PCR testing could yield
216 negative by the time of assessment due to a reduced viral load.¹ A survey of eight paediatric
217 patients showed an average of 19.6 days delay between chilblains symptom onset and
218 visiting a dermatology clinic,¹³ and a case series spanning 8 countries, showed that chilblains
219 lasted a median of 14 days.⁸ By contrast, it has been reported that in subgroups of patients
220 with COVID-19-associated-chilblains, PCR results were positive at day 8 of testing but
221 became negative by day 14.²³ Thus, these factors could explain the low rates of positive PCR
222 findings demonstrated in a number of studies.^{4, 15}

223 Despite this, our study still showed an association between confirmed COVID-19 cases and
224 chilblains in the same week, and no statistically significant associations were found when
225 delays between chilblains and COVID-19 disorder was analysed. This could be explained by
226 the widespread use of telehealth during the pandemic which would have meant that
227 chilblains diagnoses temporally coincided with COVID-19 infections.²⁴ Nevertheless, time
228 delays in association with suspected COVID were found and further investigation is needed
229 to ascertain whether COVID-19 infection plays a role in the development of chilblains.

230 In addition to a high proportion of chilblains in our paediatric age group (18.7%), a key
231 finding of our study was that the association of COVID-19 infection was greatest with
232 chilblains presentations in 0–16-year-old children. Consistent with our study, chilblain-like
233 lesions in the context of COVID-19 disease have been more commonly reported in teenagers

234 and young adults.^{1, 2, 8, 21} Paediatric patients with chilblains often lack respiratory
235 symptoms¹⁴ and have a low rate of positive PCR for COVID-19 infection.^{16, 25} It has been
236 proposed that children and young adults have a more robust innate immune response
237 leading to reduced viral load and negative PCR tests.^{20, 21} These findings stand in contrast to
238 idiopathic chilblains which are historically more common in middle-aged people⁷ and very
239 rarely reported in children.²⁶ This may imply that chilblain-like lesions in COVID-19 have a
240 different pathophysiology from idiopathic chilblains and requires further investigation.

241 The key advantage of our study compared to existing literature is that our ecological study
242 design yields a significant sample size. This adds significant power to our analysis and the
243 findings of our study. This study design also enabled us to meaningfully analyse whether
244 leads and lags existed between the timing of our diagnoses. Decreasing temperature is a key
245 cause of chilblains presentations and our study accounted for this by including these data in
246 our analysis. This means that the increase in chilblains presentations in 2020 and 2021 could
247 be more reliably associated with COVID-19. Additionally, the low p-value for significance in
248 our study gives greater confidence in the strength of our associations.

249 Nevertheless, there are some key limitations to our dataset. Over the course of the
250 pandemic, most COVID-19 diagnoses in Victoria were not made in a GP setting. As such, our
251 chilblains diagnosis data are only a subset of all COVID-19 infections that occurred in the last
252 two years. There is also uncertainty around how general practitioners coded COVID-19
253 diagnoses and whether there was a time delay between a patient having a confirmed
254 COVID-19 infection and their general practice visit at which this diagnosis would have been
255 recorded. We included suspected COVID-19 diagnosis in our analysis for completion, but this
256 is an unreliable measure of COVID-19 infection in the state and may not accurately

257 represent circulation of COVID-19 infections in Victoria. An additional factor to consider is
258 that a significant proportion of cases in Victoria were diagnosed through state-run testing
259 hubs with minimal notification back to GPs. This may have skewed our results and masked
260 possible lead and lag associations between chilblains and COVID-19.

261 Ultimately, the ecological analysis conducted in this study means that we can only
262 demonstrate associations between our datasets, and a causal relationship between COVID-
263 19 infection and chilblains presentations cannot be confirmed. Nevertheless, our findings
264 lay the foundation for future research which may confirm a causal relationship, as well as
265 ascertain the pathophysiology and aetiology of chilblains due to COVID-19 infection.

266 Conclusion

267 Our Victorian ecological study of chilblains and COVID-19 showed a significant association
268 between these presentations in Victorian general practices during the first two years of the
269 COVID-19 pandemic. Using novel statistical methodology, our study can inform
270 epidemiological understanding of COVID-19 circulation in a given region and population.
271 Additionally, existing research to ascertain the causal relationship between the novel
272 coronavirus and chilblains is scant. However, the size of association found in our study
273 demonstrates that further investigation is warranted.

274 Finally, these findings have significant implications for the potential use of large-scale
275 primary care data for monitoring the circulation of COVID-19, using chilblains presentations
276 as a surrogate measure for the spread of COVID-19 infections.

277

Bibliography:

278

- 279 1. Galvan Casas C, Catala A, Carretero Hernandez G, Rodriguez-Jimenez P, Fernandez-
280 Nieto D, Rodriguez-Villa Lario A, et al. Classification of the cutaneous manifestations of
281 COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J
282 Dermatol. 2020;183(1):71-7.
- 283 2. Daneshgaran G, Dubin DP, Gould DJ. Cutaneous Manifestations of COVID-19: An
284 Evidence-Based Review. Am J Clin Dermatol. 2020;21(5):627-39.
- 285 3. Landa N, Mendieta-Eckert M, Fonda-Pascual P, Aguirre T. Chilblain-like lesions on
286 feet and hands during the COVID-19 Pandemic. Int J Dermatol. 2020;59(6):739-43.
- 287 4. McCleskey PE, Zimmerman B, Lieberman A, Liu L, Chen C, Gorouhi F, et al.
288 Epidemiologic Analysis of Chilblains Cohorts Before and During the COVID-19 Pandemic.
289 JAMA Dermatol. 2021;157(8):947-53.
- 290 5. Kashetsky N, Mukovozov IM, Bergman J. Chilblain-Like Lesions (CLL) Associated With
291 COVID-19 ("COVID Toes"): A Systematic Review. J Cutan Med Surg.
292 2021:12034754211004575.
- 293 6. Nyssen A, Benhadou F, Magnee M, Andre J, Koopmansch C, Wautrecht JC. Chilblains.
294 Vasa. 2020;49(2):133-40.
- 295 7. Cappel JA, Wetter DA. Clinical characteristics, etiologic associations, laboratory
296 findings, treatment, and proposal of diagnostic criteria of pernio (chilblains) in a series of
297 104 patients at Mayo Clinic, 2000 to 2011. Mayo Clin Proc. 2014;89(2):207-15.

- 298 8. Freeman EE, McMahon DE, Lipoff JB, Rosenbach M, Kovarik C, Takeshita J, et al.
299 Pernio-like skin lesions associated with COVID-19: A case series of 318 patients from 8
300 countries. *J Am Acad Dermatol.* 2020;83(2):486-92.
- 301 9. Balestri R, Magnano M, Rizzoli L, Rech G. Do we have serological evidences that
302 chilblain-like lesions are related to SARS-CoV-2? A review of the literature. *Dermatol Ther.*
303 2020;33(6):e14229.
- 304 10. Department of Health. Victoria PHNs boundaries across the state. Canberra:
305 Department of Health; April 2018. Available from:
306 [https://www.health.gov.au/resources/publications/victoria-primary-health-networks-phn-](https://www.health.gov.au/resources/publications/victoria-primary-health-networks-phn-boundary-maps)
307 [boundary-maps](https://www.health.gov.au/resources/publications/victoria-primary-health-networks-phn-boundary-maps)
- 308 11. Organisation IHTSD. SNOMED International: International Health Terminology
309 Standards Development Organisation 2021. Available from: <https://www.snomed.org/>
- 310 12. R Development Core Team. R: A language and environment for statistical computing.
311 Vienna, Austria: R Foundation for Statistical Computing; 2010.
- 312 13. RStudio Team. RStudio: Integrated Development Environment for R. Boston, MA
313 2015.
- 314 14. Garcia-Lara G, Linares-Gonzalez L, Rodenas-Herranz T, Ruiz-Villaverde R. Chilblain-
315 like lesions in pediatrics dermatological outpatients during the COVID-19 outbreak.
316 *Dermatol Ther.* 2020;33(5):e13516.
- 317 15. Recalcati S, Fantini F. Chilblain-like lesions during the COVID-19 pandemic: early or
318 late sign? *Int J Dermatol.* 2020;59(8):e268-e9.
- 319 16. El Hachem M, Diociaiuti A, Concato C, Carsetti R, Carnevale C, Ciofi Degli Atti M, et al.
320 A clinical, histopathological and laboratory study of 19 consecutive Italian paediatric

- 321 patients with chilblain-like lesions: lights and shadows on the relationship with COVID-19
322 infection. *J Eur Acad Dermatol Venereol.* 2020;34(11):2620-9.
- 323 17. Gisondi P, S PI, Bordin C, Alaibac M, Girolomoni G, Naldi L. Cutaneous manifestations
324 of SARS-CoV-2 infection: a clinical update. *J Eur Acad Dermatol Venereol.* 2020;34(11):2499-
325 504.
- 326 18. Piccolo V, Neri I, Filippeschi C, Oranges T, Argenziano G, Battarra VC, et al. Chilblain-
327 like lesions during COVID-19 epidemic: a preliminary study on 63 patients. *J Eur Acad*
328 *Dermatol Venereol.* 2020;34(7):e291-e3.
- 329 19. Zhao Q, Fang X, Pang Z, Zhang B, Liu H, Zhang F. COVID-19 and cutaneous
330 manifestations: a systematic review. *J Eur Acad Dermatol Venereol.* 2020;34(11):2505-10.
- 331 20. Cappel MA, Cappel JA, Wetter DA. Pernio (Chilblains), SARS-CoV-2, and COVID Toes
332 Unified Through Cutaneous and Systemic Mechanisms. *Mayo Clin Proc.* 2021;96(4):989-
333 1005.
- 334 21. Neri I, Viridi A, Corsini I, Guglielmo A, Lazzarotto T, Gabrielli L, et al. Major cluster of
335 paediatric 'true' primary chilblains during the COVID-19 pandemic: a consequence of
336 lifestyle changes due to lockdown. *J Eur Acad Dermatol Venereol.* 2020;34(11):2630-5.
- 337 22. Damsky W, Peterson D, King B. When interferon tiptoes through COVID-19: Pernio-
338 like lesions and their prognostic implications during SARS-CoV-2 infection. *J Am Acad*
339 *Dermatol.* 2020;83(3):e269-e70.
- 340 23. Freeman EE, McMahon DE, Hruza GJ, Lipoff JB, French LE, Fox LP, et al. Timing of PCR
341 and antibody testing in patients with COVID-19-associated dermatologic manifestations. *J*
342 *Am Acad Dermatol.* 2021;84(2):505-7.

- 343 24. Snoswell CL, Caffery LJ, Haydon HM, Thomas EE, Smith AC. Telehealth uptake in
344 general practice as a result of the coronavirus (COVID-19) pandemic. *Aust Health Rev.*
345 2020;44(5):737-40.
- 346 25. Hubiche T, Cardot-Leccia N, Le Duff F, Seitz-Polski B, Giordana P, Chiaverini C, et al.
347 Clinical, Laboratory, and Interferon-Alpha Response Characteristics of Patients With
348 Chilblain-like Lesions During the COVID-19 Pandemic. *JAMA Dermatol.* 2021;157(2):202-6.
- 349 26. Simon TD, Soep JB, Hollister JR. Pernio in pediatrics. *Pediatrics.* 2005;116(3):e472-5.
350
351

352 S1:

353 Appendix A: Chilblains, COVID-19 disorder and Suspected COVID-19 disorder lead and

354 lag analysis results

355 *Table 2: COVID-19, Suspected COVID-19 and Temperature associations with Chilblains with*

356 *leads and lags*

357




Figure 1

Chilblains, COVID-19 and Minimum Temperature 2017-2021

● Chilblains ● COVID-19 Disorder ● Suspected COVID-19 Disorder ● Min Temperature (degC)




Figure 2